Twist Bioscience - TWST Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TWST shares.
View TWST analyst ratings or view top-rated stocks.

4 brokers have issued 12-month target prices for Twist Bioscience's stock. Their TWST share price forecasts range from $45.00 to $56.00. On average, they predict the company's share price to reach $51.50 in the next year. This suggests a possible upside of 31.7% from the stock's current price.
View analysts price targets for TWST or view top-rated stocks among Wall Street analysts.

Twist Bioscience's stock was trading at $77.39 on January 1st, 2022. Since then, TWST stock has decreased by 49.5% and is now trading at $39.11.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our TWST earnings forecast.

Twist Bioscience Co. (NASDAQ:TWST) announced its quarterly earnings data on Friday, August, 5th. The company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.30) by $0.22. The business had revenue of $56.10 million for the quarter, compared to the consensus estimate of $52.06 million. Twist Bioscience had a negative net margin of 112.91% and a negative trailing twelve-month return on equity of 29.61%. The company's quarterly revenue was up 60.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.82) EPS.

Twist Bioscience issued an update on its FY 2022 earnings guidance on Friday, September, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $203.00 million-$203.00 million, compared to the consensus revenue estimate of $196.91 million.

44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

(TWST) raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TWST stock can currently be purchased for approximately $39.11.

Twist Bioscience (NASDAQ:TWST) has a market capitalization of $2.20 billion and generates $132.33 million in revenue each year. The company earns $-152,100,000.00 in net income (profit) each year or ($3.96) on an earnings per share basis.

The company employs 652 workers across the globe.

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com.